Bigger, fewer, tougher: the new era of China-US biotech partnerships
SCMP·- Cross-border biotech deals between China and the U.S. face complexities and potential slowdowns due to increased geopolitical scrutiny and regulatory hurdles, as noted by industry analysts. - Despite this, a trend of Western pharmaceutical companies partnering with Chinese biotech is expected to accelerate, with the out-licensing market projected to reach approximately $240 billion in 2026. - Additional U.S. legislation aiming to screen investments may complicate such partnerships, but strong demand for Chinese drug assets, driven by lower costs and promising candidates, persists.